BB will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
The transaction is expected to close in the Q4FY22
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
Vikas Lifecare has already paid Rs. 25 million to the Advik bankers till date and the remaining amount shall also be paid within July 2021, making Advik a debt free company
With the acquisition of these further shares, TWPL has now become company's subsidiary.
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
The dispute stems from an earlier circular by Zuventus allegedly accusing Zorvia of market sabotage
Marking three years of the National Diagnostics Catapult (NDxC), the conclave launched the Impact Report and unveiled environmental surveillance kits
Subscribe To Our Newsletter & Stay Updated
